BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Lotus Tissue Repair Pioneers New Treatment for Rare and Disfiguring Disorder, Raises $26 Million From Third Rock


6/30/2011 8:02:10 AM

Lotus Tissue Repair Inc. has launched as a spinout from Third Rock Ventures, which led the Cambridge biotech’s $26 million Series A funding round. The funds will be used to develop the technology it licensed from the University of Southern California into a collagen-based therapy for a rare skin disorder. Philip Reilly, a partner at Third Rock, is one of the co-founders of the company and is serving as interim chief medical officer, according to the Lotus Tissue website. CEO Mark de Souza, formerly a vice president of business development with Dyax Corp., and CFO James Fordyce, managing partner of private advisory firm MEDNA Partners LLC, are the other co-founders of Lotus Tissue Repair.

Read at Mass High Tech
Read at Boston Globe
Read at Xconomy


 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->